Usefulness of Enhanced Liver Fibrosis, Glycosylation Isomer of Mac-2 Binding Protein, Galectin-3, and Soluble Suppression of Tumorigenicity 2 for Assessing Liver Fibrosis in Chronic Liver Diseases-Reference-Cited by-同舟云学术

Usefulness of Enhanced Liver Fibrosis, Glycosylation Isomer of Mac-2 Binding Protein, Galectin-3, and Soluble Suppression of Tumorigenicity 2 for Assessing Liver Fibrosis in Chronic Liver Diseases

Published:2018-07-28 Issue:4 Volume:38 Page:331-337
ISSN:2234-3806
Container-title:Annals of Laboratory Medicine
language:en
Short-container-title:Ann Lab Med

Author:

Moon Hee-Won¹,Park Mikyoung¹,Hur Mina¹,Kim Hanah¹,Choe Won Hyeok²,Yun Yeo-Min¹

Affiliation:

1. Department of Laboratory Medicine, Konkuk University School of Medicine, Seoul, Korea

2. Department of Internal Medicine, Konkuk University School of Medicine, Seoul, Korea

Publisher

Annals of Laboratory Medicine

Subject

Biochemistry, medical,Clinical Biochemistry,General Medicine

Link

https://synapse.koreamed.org/pdf/10.3343/alm.2018.38.4.331

Reference33 articles.

1. Mechanisms of Hepatic Fibrogenesis

2. Clinical application of transient elastography in patients with chronic viral hepatitis receiving antiviral treatment

3. Hepatitis B: Liver fibrosis and hepatocellular carcinoma

4. Lamivudine as Initial Treatment for Chronic Hepatitis B in the United States

5. Clinical Application of Liver Stiffness Measurement Using Transient Elastography: A Surgical Perspective

Cited by 26 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Atropisomerism Observed in Galactose-Based Monosaccharide Inhibitors of Galectin-3 Comprising 2-Methyl-4-phenyl-2,4-dihydro-3H-1,2,4-triazole-3-thione;Journal of Medicinal Chemistry;2024-08-05

2. Evaluation of Mac-2 binding protein glycosylation isomer (M2BPGi) as a diagnostic marker for staging liver fibrosis: a meta-analysis;PeerJ;2024-06-25

3. Galectin-3 and Severity of Liver Fibrosis in Metabolic Dysfunction-Associated Fatty Liver Disease;Protein & Peptide Letters;2024-04

4. Evaluation of soluble suppression of tumorigenicity 2 (sST2) as serum marker for liver fibrosis;BMC Gastroenterology;2024-01-30

5. Galectin-3: therapeutic targeting in liver disease;Expert Opinion on Therapeutic Targets;2023-09-02